Tessenderlo Group completes sale of pharmaceutical ingredients activities
(Thomson Reuters ONE) -
Tessenderlo Group (NYSE Euronext: TESB) announced today that it has completed
the sale of its pharmaceutical ingredients activities in Calaire (France) and
Farchemia (Italy) to International Chemical Investors Group (ICIG), a private
industrial holding company.
On October 9 2012, the group announced its intention to divest the
pharmaceutical ingredients activities Calaire and Farchemia. Information and
consultation procedures were completed early November. After clearance by the
merger control authorities , the sale was completed on December 5 2012.
This divestment is in line with Tessenderlo Group's strengthened focus on
specialty products and services in the areas of food, agriculture, water
management and valorizing bio-residuals.
Calaire and Farchemia employ some 360 employees.
Tessenderlo Group is a worldwide specialty company, focused on food,
agriculture, water management and on valorizing bio-residuals. The group employs
about 7,500 people and is a leader in most of its markets, with a consolidated
revenue of 2.1 billion EUR in 2011. Tessenderlo Chemie NV is listed on NYSE
Eurolist by Euronext Brussels and is part of Next 150 and BEL Mid indices.
Financial News wires: Bloomberg: TESB BB - Reuters: TesBt.BR - Datastream: B:Tes
International Chemical Investors Group (ICIG) is a privately owned industrial
holding company focusing on mid-sized chemicals and pharmaceutical businesses.
Since inception in 2004, ICIG has acquired 17 businesses, all of which have
origins in major global chemical or pharmaceutical corporations and are
independently managed. ICIG companies currently employ more than 3,300 people
and operate 17 manufacturing facilities in Europe and the United States with
total sales of approximately ?700 million. For more info about International
Chemical Investors Group: http://www.ic-investors.com
Media Relations Investor Relations
Kathleen IWENS Philip LUDWIG
Tel: +32 (0) 478 664 555 Tel: +32 2 639 16 58
This press release is available in Dutch, French and English on the corporate
website www.tessenderlogroup.com - under 'News & Media'
Pour lire le communiqué de presse complet en Français, cliquez ici:
http://hugin.info/133974/R/1664104/539797.pdf
To read the full press release in English, click here:
http://hugin.info/133974/R/1664104/539795.pdf
Hier kan je het volledige bericht in het Nederlands lezen:
http://hugin.info/133974/R/1664104/539796.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Tessenderlo Group via Thomson Reuters ONE
[HUG#1664104]
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
" alt="Arrowstar Completes Benefication Testing from 105 samples, at Port Snettisham, Alaska, Iron Ore ProjectDatum: 12.12.2012 - 07:01 Uhr
Sprache: Deutsch
News-ID 211891
Anzahl Zeichen: 3450
contact information:
Town:
Brussels
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 152 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Tessenderlo Group completes sale of pharmaceutical ingredients activities"
steht unter der journalistisch-redaktionellen Verantwortung von
Tessenderlo Group (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
